Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

STOCK-BASED COMPENSATION (Details 3)

STOCK-BASED COMPENSATION (Details 3) (USD $)	3 Months Ended	12 Months Ended			1 Months Ended
STOCK-BASED COMPENSATION (Details 3) (USD $)	Dec. 31, 2014	Dec. 31, 2014 item	Dec. 31, 2013	Dec. 31, 2012	Feb. 28, 2014
Stock Based Compensation
Number of homogenous groups for purposes of determining fair values of options		3
Share-based compensation	$ 1,500,000	$ 9,787,000	$ 7,166,000	$ 12,617,000
Employee Stock [Member]
Weighted-average assumptions relating to options granted
Risk-free interest rate (as a percent)		0.30%	0.20%	0.20%
Expected term (in years)		1 year 8 months 12 days	1 year 4 months 24 days	1 year 2 months 12 days
Dividend yield (as a percent)		0.00%	0.00%	0.00%
Expected volatility (as a percent)		66.00%	64.40%	47.40%
Employee Stock Option [Member]
Stock Based Compensation
Contractual term of the option		10 years
Weighted-average assumptions relating to options granted
Risk-free interest rate (as a percent)		2.20%	1.10%	0.90%
Expected term (in years)		6 years 6 months	5 years 4 months 24 days	5 years 6 months
Dividend yield (as a percent)		0.00%	0.00%	0.00%
Expected volatility (as a percent)		74.40%	72.20%	81.50%
Shares Available For Grant
Outstanding at the beginning of the period (in shares)		9,045,761	3,198,586	4,707,753
Authorized for grant (in shares)			7,775,000	600,000
Granted (in shares)		(3,467,120)	(3,140,956)	(2,149,266)
Cancelled (in shares)		2,017,430	1,213,131	40,099
Outstanding at the end of the period (in shares)	7,596,071	7,596,071	9,045,761	3,198,586
Number of Shares Underlying Options
Outstanding at the beginning of the period (in shares)		15,532,202	13,604,377	11,749,359
Granted (in shares)		3,467,120	3,140,956	2,149,266
Exercised (in shares)		(11,219)		(254,149)
Cancelled (in shares)		(2,017,430)	(1,213,131)	(40,099)
Outstanding at the end of the period (in shares)	16,970,673	16,970,673	15,532,202	13,604,377
Vested and expected to vest (in shares)	16,861,378	16,861,378
Exercisable (in shares)	14,243,893	14,243,893	13,246,612	12,841,378
Weighted Average Exercise Price
Outstanding at the beginning of the period (in dollars per share)		$ 10.55	$ 11.52	$ 12.07
Granted (in dollars per share)		$ 3.39	$ 5.46	$ 8.13
Exercised (in dollars per share)		$ 3.44		$ 7.08
Cancelled (in dollars per share)		$ 10.75	$ 8.26	$ 19.60
Outstanding at the end of the period (in dollars per share)	$ 9.07	$ 9.07	$ 10.55	$ 11.52
Vested and expected to vest (in dollars per share)	$ 9.10	$ 9.10
Exercisable (in dollars per share)	$ 10.09	$ 10.09	$ 11.44	$ 11.75
Weighted Average Remaining Contractual Term (in years)
Outstanding at the end of the period		5 years 9 months 15 days
Exercisable		5 years 2 months 9 days
Aggregate Intrinsic Value
Outstanding at the end of the period (in dollars)	25,140	25,140
Exercisable	983	983
Number of nonvested stock options (in shares)	2,726,779	2,726,779	2,281,966
Intrinsic value of nonvested stock options	24,000	24,000	14,000
Aggregate intrinsic value of options exercised		10,000	0	701,000
Unrecognized compensation cost related to purchase plan	302,000	302,000
Weighted-average recognition period of unamortized compensation cost		1 year 10 months 24 days	1 year 8 months 12 days
Number of shares vested		2,456,622	1,513,339
Weighted-average exercise price for shares vested during the period (in dollars per share)		$ 4.74	$ 6.64
Additional disclosures
Options granted (in shares)		(3,467,120)	(3,140,956)	(2,149,266)
Options cancelled (in shares)		2,017,430	1,213,131	40,099
Options outstanding at the end of the period (in shares)	16,970,673	16,970,673	15,532,202	13,604,377
Grant-date weighted-average fair value (in dollars per share)		$ 2.32	$ 3.34	$ 5.44
Total unrecognized compensation cost, net of estimated forfeitures	4,800,000	4,800,000
Shares of common stock available for future grant	7,596,071	7,596,071	9,045,761	3,198,586
Options exercised during the period (in shares)		11,219		254,149
Employee Stock Option [Member] \| Consultant [Member]
Stock Based Compensation
Contractual term of the option		10 years
Share-based compensation		$ 38,000	$ 36,000	$ 55,000
Number of Shares Underlying Options
Exercised (in shares)		0
Additional disclosures
Options exercised during the period (in shares)		0
Performance Shares [Member]
Shares Available For Grant
Granted (in shares)		950,000			950,000
Cancelled (in shares)		250,000
Number of Shares Underlying Options
Granted (in shares)		(950,000)			(950,000)
Cancelled (in shares)		(250,000)
Outstanding at the end of the period (in shares)	700,000	700,000
Additional disclosures
Options granted (in shares)		950,000			950,000
Options cancelled (in shares)		250,000
Options outstanding at the end of the period (in shares)	700,000	700,000